Anti-IL-2 antibody

Cat.#: 106349

Special Price 145.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-IL-2 antibody
  • Documents
  • Description
    Mouse monoclonal to IL-2
  • Tested applications
    IHC-P
  • Species reactivity
    Rat Interleukin-2 / IL-2
    No cross-reactivity in ELISA with Human IL2; Mouse IL2
  • Alternative names
    Il2 antibody; IL2 antibody; IL-2 antibody; IL-2 antibody; lymphokine antibody; TCGF antibody; TCGF antibody; DN-144H19.3 antibody
  • Immunogen
  • Isotype
    Mouse IgG2b
  • Preparation
    This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Rat Interleukin-2 / IL-2 (rR Interleukin-2 / IL-2; P17108; Ala21-Gln155). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
  • Clonality
    Monoclonal
  • Formulation
    0.2 μm filtered solution in PBS with 5% trehalose
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    IHC-P: 10-30 μg/mL

  • Validations

    Interleukin-2 / IL-2 Antibody, Mouse MAb, Immunohistochemistry

    Interleukin-2 / IL-2 Antibody, Mouse MAb, Immunohistochemistry

    Immunochemical staining of rat IL2 in rat spleen (from 2 donors) with mouse monoclonal antibody (15 µg/mL, formalin-fixed paraffin embedded sections).

  • Background
    Interleukin-2, also known as T-cell growth factor, TCGF, Aldesleukin and IL2, is a secreted protein which belongs to the IL-2 family. Interleukin-2 / IL-2 was the first interleukin molecule to be discovered. Interleukin-2 / IL-2 molecule was first purified to homogeneity by immunoaffinity chromatography by Kendall Smith and his team at Dartmouth Medical School. Interleukin-2 / IL-2 was also the first cytokine shown to mediate its effects via a specific IL-2 receptor, and it was also the first interleukin to be cloned and expressed from a complementary DNA (cDNA) library. Interleukin-2 / IL-2 was designated number 2 because Smith's data at the time indicated that IL-1, produced by macrophages, facilitates IL-2 production by T lymphocytes (T cells). Interleukin-2 / IL-2 is produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Interleukin-2 / IL-2 is normally produced by the body during an immune response. When environmental substances (molecules or microbes) gain access to the body, these substances (termed antigens) are recognized as foreign by antigen receptors that are expressed on the surface of lymphocytes. Antigen binding to the T cell receptor (TCR) stimulates the secretion of Interleukin-2 / IL-2, and the expression of IL-2 receptors IL-2R. The IL-2 / IL-2R interaction then stimulates the growth, differentiation and survival of antigen-selected cytotoxic T cells via the activation of the expression of specific genes. Interleukin-2 / IL-2 can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells. The World Reference Standard for Interleukin-2 / IL-2 is produced by the National Institute of Biological Standards and Control in the UK. A recombinant form of Interleukin-2 / IL-2 for clinical use is manufactured by Chiron Corporation with the brand name Proleukin. It has been approved by the Food and Drug Administration (FDA) for the treatment of cancers (malignant melanoma, renal cell cancer), and is in clinical trials for the treatment of chronic viral infections, and as a booster (adjuvant) for vaccines. The use of Interleukin-2 / IL-2 in HIV therapy has been found to be ineffective.
  • References
    • Smith KA, et al.,1980,  J. Exp. Med.151 (6): 1551-6. 
    • Smith KA, et al.,1980, Nature. 287 (5785): 853-5.
    • Taniguchi T, et al.,1983, Nature. 302 (5906): 305.
    • Cantrell DA, et al.,1984, Science. 224 (4655): 1312-6. 
    • Smith KA, et al.,1988, Science. 240 (4856): 1169-76.
    • Wang X. et al., 2005, Science 310:1159-63.
    • Stauber D.J. et al., 2006, Proc. Natl. Acad. Sci. USA. 103: 2788-93.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"